---
title: "BioCryst Pharmaceuticals, Inc. (BCRX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BCRX.US.md"
symbol: "BCRX.US"
name: "BioCryst Pharmaceuticals, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T06:36:59.609Z"
locales:
  - [en](https://longbridge.com/en/quote/BCRX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BCRX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BCRX.US.md)
---

# BioCryst Pharmaceuticals, Inc. (BCRX.US)

## Company Overview

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.biocryst.com](https://www.biocryst.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: C (0.42)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 90 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 75.92% |  |
| Net Profit YoY | -756.52% |  |
| P/B Ratio | -4.06 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2249681561.40 |  |
| Revenue | 885716000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 91.07% | A |
| Profit Margin | -51.71% | E |
| Gross Margin | 58.00% | B |
| Revenue YoY | 75.92% | A |
| Net Profit YoY | -756.52% | E |
| Total Assets YoY | -3.12% | D |
| Net Assets YoY | -22.55% | E |
| Cash Flow Margin | -68.36% | E |
| OCF YoY | 75.92% | A |
| Turnover | 1.87 | A |
| Gearing Ratio | 219.09% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - BioCryst Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "75.92%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-756.52%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-4.06",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2249681561.40",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "885716000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "91.07%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-51.71%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "58.00%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "75.92%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-756.52%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-3.12%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-22.55%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-68.36%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "75.92%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "1.87",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "219.09%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.80 | 374/386 | 8.95 | 8.71 | 8.17 |
| PB | -3.97 | 503/386 | - | - | - |
| PS (TTM) | 2.48 | 63/386 | 3.36 | 2.71 | 2.49 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 70% |
| Overweight | 3 | 30% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 8.77 |
| Highest Target | 32.00 |
| Lowest Target | 14.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BCRX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BCRX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BCRX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BCRX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**